Why and How We Disclose Payments to Health Care Professionals

We want people to know, and understand, what we do: We want to be clear about our payments to health care providers and clinical investigators. Sharing this information in a simple and uniform manner helps patients and other interested parties to accurately understand these valuable relationships.

We have a record of being clear about what we do: This is a natural extension of our commitment to providing greater transparency into our business operations:

• 2007: Pfizer led the industry by reporting its post-marketing commitments on Pfizer.com.
• 2008: Pfizer began reporting its non-clinical grants and charitable contributions to patient, medical and scientific organizations.
• 2009: Pfizer began collecting physician payment data for public reporting.

We report payments for a range of activities with physicians: We want patients to understand the way we work with health care professionals:

• We include payments to practicing physicians and other health care providers, as well as to principal investigators and institutions for Phase I-IV clinical trials sponsored by Pfizer, begun after July 1, 2009.
• We also report payments to major institutions for clinical trials ongoing as of July 1, 2009, and to principal investigators and all other entities for investigator-initiated research.
• We subsequently included these disclosures, as a requirement, in Pfizer's August 2009 Corporate Integrity Agreement with the Office of the Inspector General of the Department of Health and Human Services.